In stable patients with coronary stenting receiving standard antiplatelet therapy , vorapaxar administered for long-term secondary prevention significantly reduced ARC definite ST , including very late ST. ( Trial to Assess the Effects of Vorapaxar [ SCH 530348 ; MK-5348 ] in Preventing Heart Attack and Stroke in Patients With Atherosclerosis [ TRA 2 P-TIMI 50 ] [ P04737 ] ; NCT00526474 ) .